Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.56 |
| ▸ | CCR1 | P32246 | 1/20 | 0.56 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150575 | 0.93 | KCNE1 (0.56) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL27616343 | 0.91 | KCNE1 (0.54) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL6017760 | 0.91 | SMN1; SMN2 (0.57) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL6017686 | 0.90 | KCNE1 (0.55) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL6018290 | 0.89 | KCNE1 (0.53) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL6017778 | 0.89 | KCNE1 (0.55) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL1150452 | 0.89 | KCNE1 (0.53) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL14260085 | 0.89 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2POLBTP53 | |
| SCHEMBL1150919 | 0.88 | KCNE1 (0.51) | KCNE1CCR1KCNQ1KMT2AMEN1 | |
| SCHEMBL14501759 | 0.88 | KCNE1 (0.51) | KCNE1CCR1KCNQ1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | claimed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | claimed |
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2008-11-06 | — | — | US | claimed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | claimed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | claimed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | claimed |
| WO-2011041512-A2 | COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES | EMORY UNIVERSITY (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-7037908-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | disclosed |
| WO-2004096128-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1441735-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035077-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | KCNE1 3603/4885CCR1 1055/4885KCNQ1 3423/4885 |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | DUT, CDK6, TYMS | KCNE1 3647/4885CCR1 1187/4885KCNQ1 2858/4885 |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | IMPDH1, REV1, CCNI | KCNE1 3603/4885CCR1 1055/4885KCNQ1 3423/4885 |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | IMPDH1, CCNI, REV1 | KCNE1 3802/4885CCR1 994/4885KCNQ1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.